MedTrace Logo

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT04373369 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-11-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether adding vorolanib to atezolizumab will improve the length of time that participants are cancer-free after receiving standard chemotherapy.

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Vorolanib

Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.

DRUG

Atezolizumab

Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.

Sponsors & Collaborators

  • Xcovery Holdings, Inc.

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Daniel Morgensztern, MD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2022-08-18
Completion
2025-08-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04373369 on ClinicalTrials.gov